{"id":17858,"date":"2024-12-13T14:59:08","date_gmt":"2024-12-13T06:59:08","guid":{"rendered":"https:\/\/flcube.com\/?p=17858"},"modified":"2024-12-13T14:59:34","modified_gmt":"2024-12-13T06:59:34","slug":"curegene-pharmaceutical-gets-nmpa-approval-for-antiplatelet-drug-cg-0255","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17858","title":{"rendered":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255"},"content":{"rendered":"\n<p>Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS). <\/p>\n\n\n\n<p><strong>Category 1 Drug CG-0255: A P2Y12 Receptor Antagonist<\/strong><br>The Category 1 drug CG-0255 is a P2Y12 receptor antagonist designed for patients with ACS undergoing percutaneous coronary intervention (PCI), such as angioplasty. The drug&#8217;s injectable formulation presents several advantages over current oral antiplatelet therapies, including a faster onset of action, enhanced efficacy, and increased bioavailability. These benefits could potentially lead to improved patient outcomes in the critical care settings where rapid and effective treatment is paramount.<\/p>\n\n\n\n<p><strong>Overcoming Challenges in Existing Antiplatelet Therapies<\/strong><br>One of the distinctive features of CG-0255 is its metabolic pathway, which addresses key challenges in current antiplatelet drug therapies. The drug bypasses the cytochrome P450 (CYP) 2C19 enzyme system, which can vary genetically among individuals and impact the effectiveness of conventional antiplatelet medications. By overcoming this variability, CG-0255 has the potential to provide a more reliable and consistent therapeutic option for patients undergoing PCI.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":17860,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1575,69],"class_list":["post-17858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-curegene-pharmaceutical","tag-cvd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17858\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17858\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-13T06:59:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T06:59:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255\",\"datePublished\":\"2024-12-13T06:59:08+00:00\",\"dateModified\":\"2024-12-13T06:59:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1316.png\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CureGene Pharmaceutical\",\"CVD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17858#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17858\",\"name\":\"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1316.png\",\"datePublished\":\"2024-12-13T06:59:08+00:00\",\"dateModified\":\"2024-12-13T06:59:34+00:00\",\"description\":\"Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17858\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1316.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1316.png\",\"width\":1080,\"height\":607,\"caption\":\"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17858#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255 - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17858","og_locale":"en_US","og_type":"article","og_title":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255","og_description":"Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).","og_url":"https:\/\/flcube.com\/?p=17858","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-13T06:59:08+00:00","article_modified_time":"2024-12-13T06:59:34+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17858#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17858"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255","datePublished":"2024-12-13T06:59:08+00:00","dateModified":"2024-12-13T06:59:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17858"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=17858#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png","keywords":["Clinical trial approval \/ initiation","CureGene Pharmaceutical","CVD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17858#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17858","url":"https:\/\/flcube.com\/?p=17858","name":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=17858#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=17858#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png","datePublished":"2024-12-13T06:59:08+00:00","dateModified":"2024-12-13T06:59:34+00:00","description":"Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17858#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17858"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=17858#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png","width":1080,"height":607,"caption":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17858#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1316.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17858"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17858\/revisions"}],"predecessor-version":[{"id":17862,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17858\/revisions\/17862"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/17860"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}